J. Brian Byrd
@jbrianbyrd
Blood pressure research is at the interface of disciplines... & that's where I like to be | physician-investigator, editor, founder of Research Symbiont Awards
ID: 1359873758702501891
http://byrdlab.org 11-02-2021 14:36:03
1,1K Tweet
793 Followers
1,1K Following
Our new brief review on Resistant HTN is out today in JAMA Internal Medicine John Giacona, PhD, PA-C🫀 Weerapat Kositanurit UTSW Heart jamanetwork.com/journals/jamai…
Asymmetric bilateral #PrimaryAldosteronism cannot be excluded by strong adrenal vein sampling lateralization. Adina Turcu Debbie Cohen MD 🇮🇱 🇺🇸🇿🇦 Wasita W. Parksook Jun Yang Tracy Ann Williams @anandvaidya17 ahajrnls.org/3VpAveM
We investigated the contributions of renin-independent & ACTH-mediated aldosteronism in individuals with low-renin phenotype representing an entire continuum of BP. Thank you @AnandVaidya1 Jen Brown, our team members/collaborators SS endo CU Adina Turcu doi.org/10.1210/clinem…
The legendary GL Bakris, 700+ papers on PubMed, more importantly, cited almost 250,000 times. Sat at his table a few times during conferences. A delight to listen to what he had to say. Utmost respect. R.I.P. George Bakris
J. Brian Byrd Wanpen Vongpatanasin Maybe the Lewington floating curves should have a tail for stroke? Pathphysiologically, I can imagine that stroke could be related to severity of mean and peak values, whilst heart failure would be total burden of BP.
J. Brian Byrd Wanpen Vongpatanasin Yes, though one wonders what proportion of trial pts were in circled area & at time, they were smokers, with particulates, eating differently etc, so as risk profiles change, is it possible we see a different expression of BP as a multiplier of risk that differs by HMOD outcome?
J. Brian Byrd It will be interesting to look at stroke outcome from meta-analysis combining SPRINT and ESPRIT-though all cause death is lower in intensive arm <120 mmHg. At least CRHCP and STEP showed reducting in stroke when lowering to <130 for older and younger group.
"Resistant hypertension, defined as above-goal BP despite concurrent use of 3 anti-HTN drug classes in the setting of good adherence, is a good eg. of a situation in which poorly chosen medications.. " Personalized Medicine and the Treatment of HTN PMID: 30747306 Sarah Melville